Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

RCT (n=1711) found no significant differences in disease-free survival with sorafenib (median not reached for 3 years of sorafenib or placebo) or overall survival, and it should not be used as adjuvant therapy; active surveillance remains the standard of care in this population.

Journal of Clinical Oncology